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Abstract
Cancer originates from cells that have acquired mutations in genes critical for controlling cell proliferation, survival and
differentiation. Often, tumors continue to depend on these so-called driver mutations, providing the rationale for targeted
anticancer therapies. To date, large-scale sequencing analyses have revealed hundreds of mutations in human tumors.
However, without their functional validation it remains unclear which mutations correspond to driver, or rather bystander,
mutations and, therefore, whether the mutated gene represents a target for therapeutic intervention. In human colorectal
tumors, the neurotrophic receptor TRKB has been found mutated on two different sites in its kinase domain (TRKB
T695I and
TRKB
D751N). Another site, in the extracellular part of TRKB, is mutated in a human lung adenocarcinoma cell line (TRKB
L138F).
Lastly, our own analysis has identified one additional TRKB point mutation proximal to the kinase domain (TRKB
P507L)i na
human melanoma cell line. The functional consequences of all these point mutations, however, have so far remained
elusive. Previously, we have shown that TRKB is a potent suppressor of anoikis and that TRKB-expressing cells form highly
invasive and metastatic tumors in nude mice. To assess the functional consequences of these four TRKB mutations, we
determined their potential to suppress anoikis and to form tumors in nude mice. Unexpectedly, both colon cancer-derived
mutants, TRKB
T695I and TRKB
D751N, displayed reduced activity compared to that of wild-type TRKB. Consistently, upon
stimulation with the TRKB ligand BDNF, these mutants were impaired in activating TRKB and its downstream effectors AKT
and ERK. The two mutants derived from human tumor cell lines (TRKB
L138F and TRKB
P507L) were functionally
indistinguishable from wild-type TRKB in both in-vitro and in-vivo assays. In conclusion, we fail to detect any gain-of-
function of four cancer-derived TRKB point mutations.
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Introduction
Cancer is a genetic disease, with numerous somatic mutations in
proto-oncogenes and tumor suppressor genes contributing to the
malignant phenotype [1]. These genes normally control vital
processes including cell proliferation, survival or differentiation
[2]. Their mutation endows tumor cells with a selective advantage,
resulting in clonal expansion and neoplasia. Although tumors
usually harbor multiple genetic aberrations [1], inhibition of only
one or a few gene products can be sufficient to largely suppress
tumor cell proliferation or viability [3]. This has been shown to
cause tumor regression in various cancer mouse models [4–6] and
led to the concepts of ‘‘oncogene addiction’’ and ‘‘tumor
suppressor gene hypersensitivity’’ [3]. The dependency of tumor
cells on certain oncogenes and signaling pathways exposes an
‘‘Achilles’ heel’’ of cancer, which can be targeted for anticancer
therapy [7]. Based on this concept, several novel therapeutics have
been developed and are used in the clinic [8]. They include
imatinib mesylate (or ‘‘Gleevec’’/‘‘Glivec’’) for BCR-ABL inhibi-
tion in Chronic Myeloid Leukemia (CML) [9] and for KIT
inhibition in gastrointestinal stromal tumors (GIST) [10], respec-
tively. Similarly, in breast cancer patients with ERBB2 (also
named HER-2/NEU) overexpression, the monoclonal antibody
trastuzumab [11–13] and the small molecule inhibitor lapatinib
[14] are effective. A critical role for oncogenic mutations is
illustrated by the example of epidermal growth factor receptor
(EGFR/ERBB1) in Non Small Cell Lung Cancer (NSCLC),
where only a subset of patients respond to the EGFR inhibitor
gefitinib. Sequencing analyses revealed that responsive tumors
harbor specific mutations in EGFR, increasing its activation by
EGF [15].
These and other examples illustrate that the identification of
oncogenes critically required for tumor cell proliferation and
survival can lead to effective anticancer therapeutics. Therefore,
several research groups have been carrying out systematic large-
scale sequencing analyses to screen for genes that are mutated in
cancer. This strategy has led first to the identification of the BRAF
kinase as a critical oncogene in a large proportion of melanomas
and several other cancers [16]. In 2003, the group of Vogelstein,
Kinzler and Velculescu systematically sequenced the kinase
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cancers. They found 7 out of 138 genes analyzed to be mutated in
more than one tumor [17]. The same group subsequently
analyzed more than 1000 different genes in breast and colon
cancer [18], identifying up to 189 novel and known candidate
cancer genes. Likewise, Stratton, Futreal and co-workers at the
Sanger Institute sequenced first 518 full-length kinases in lung
tumors and tumor cell lines [19] and subsequently the full kinome
in ten different cancer types [20]. These and other analyses have
identified hundreds of novel somatic mutations across several
human malignancies [21]. However, a few exceptions aside, the
functional consequences of those mutations have remained largely
elusive. To select the appropriate targets for future anticancer
therapies, it will be necessary to test experimentally which of these
mutations are oncogenic and on which mutated genes tumors
depend.
We chose to investigate the neurotrophic receptor TRKB
(NTRK2), for which three somatic, non-synonymous point
mutations have been reported in the studies mentioned above
[17,19], while our own analysis has revealed another TRKB point
mutation in a human melanoma cell line. TRKB is one of three
members of the TRK receptor family, which also includes TRKA
and TRKC. TRKB preferentially binds the neurotrophin brain-
derived neurotrophic factor (BDNF) and NT4/5, while TRKA
and TRKC have high affinities to nerve growth factor (NGF) and
NT3, respectively [22]. The pan-TRK receptor p75NTR further
modulates the responsiveness of TRK receptors to neurotrophins
[22]. TRKB has been found overexpressed in a number of
aggressive human cancer types (for review see [23]). Previously, we
have shown that TRKB is a potent suppressor of anoikis (apoptosis
induced by inappropriate or absent cell adhesion) in rat epithelial
cells, and that TRKB-overexpressing cells form highly invasive
and metastatic tumors in nude mice [24]. Furthermore, our
previously reported structure-function analysis demonstrated that
all these functions depend on TRKB kinase activity in this
experimental system [25]. More recently, we have demonstrated
for TRKB-transformed rat epithelial cells that increased MAPK
activity signals via twist and snail to induce Epithelial-Mesenchy-
mal Transition (EMT)-like transformation, anoikis suppression
and metastasis [26]. As two of the identified cancer-derived TRKB
point mutations map within the kinase domain, possibly affecting
its enzymatic activity, it is conceivable that they act oncogenically
and correspond to driver mutations. The aim of this study was,
therefore, to assess the functional consequences of four indepen-
dent human cancer-derived TRKB point mutations.
Results
Identification of human cancer-derived TRKB point
mutants and generation of cell systems
Two non-synonymous point mutations within the kinase
domain of the TRKB gene have been discovered in colorectal
tumors: TRKB
T695I and TRKB
D751N [17] (the numbering of all
amino acid sequences refers to the full length human TRKB
protein, accession number NP_006171.2). Another TRKB point
mutation, TRKB
L138F, was identified in the lung adenocarcinoma
cell line NCI-H2009 [19]. This mutation lies within the leucine-
rich domain of the extracellular part of the receptor, which has
been shown to be required for binding of the TRKB ligand brain-
derived neurotrophic factor (BDNF) and activation of the TRKB
receptor [25,27,28]. We confirmed the presence of this mutation
by sequencing genomic DNA (gDNA) isolated from NCI-H2009
cells (Figure 1A, left panel). The presence of a double peak
(thymidine and cytosine) indicates that the mutation is heterozy-
gous, consistent with the original report [19]. It results in the
substitution of leucine by phenylalanine. To search for more
cancer-associated TRKB point mutations, we sequenced the exons
comprising the TRKB kinase domain from genomic DNA of 28
human tumor cell lines, from several tissue origins (data not
shown). This analysis revealed one additional TRKB point
mutation, in the MDA-MB-435 melanoma cell line. (The MDA-
MB-435 cell line seems to have been classified wrongly in the past
[29]. Whereas it was originally isolated from a patient with breast
cancer [30,31], recent analysis indicated that the currently
available cell line is of melanoma origin [32,33]). The TRKB
mutation identified in MDA-MB-435 cells is C1520T, resulting in
a substitution of proline 507 with leucine (TRKB
P507L). In this
case, the sequencing of gDNA revealed a single peak only
(Figure 1A right panel), suggesting that the mutation is
homozygous. The P507 residue is located proximal to the kinase
domain in the intracellular part of the receptor. Figure 1B shows a
schematic overview of the positions of all human cancer-derived
TRKB point mutations analyzed in this study.
We assessed whether these four cancer-derived TRKB point
mutations correspond to gain-of-function mutations associated
with increased oncogenic potential. We performed this analysis in
rat epithelial cells first, because they are highly sensitive to TRKB-
mediated oncogenic transformation, as marked by an EMT-like
morphologic transformation, anoikis resistance and metastatic
tumor formation in nude mice [24–26]. To this end, we cloned
wild-type and mutant TRKB into the retroviral pBabe-puro
expression vector and transduced rat intestinal epithelial (RIE-1)
cells as well as E1A-immortalized rat kidney epithelial (RK3E)
cells. Both cell lines are immortalized, yet non-oncogenic in
athymic mice. As a negative control, we expressed a kinase-
inactive mutant of TRKB, TRKB
K588M [34], which we previously
demonstrated to be incapable of oncogenically transforming RIE-
1 cells [25,26]. We confirmed by western blot analysis that all
TRKB mutants were expressed to similar levels as wild-type
TRKB (Figure 1C for RIE-1 cells, Figure S1A for RK3E cells).
Consistent with our previous observations [25], we detected
TRKB as multiple species on an SDS-polyacrylamide gel, most
likely reflecting differentially glycosylated species [35]. Further-
more, by performing a cell surface biotinylation assay we ensured
that at least a detectable fraction of all the TRKB mutants
properly localized to the cell membrane [36] (Figure 1D). We thus
generated a cell system allowing us to compare the activities and
functions of the different TRKB mutants side by side.
Transforming potential of human cancer-derived TRKB
point mutants in vitro
Like most kinases, TRKB needs a minimal level of activation to
transform epithelial cells. We hypothesized that if the cancer-
derived TRKB mutations confer a gain of function, they may
transform epithelial cells even in the absence (or with reduced
levels) of BDNF. However, when we tested the various TRKB
mutants in the absence of co-expressed ligand, none of them
induced a spindle-shaped cell morphology (Figure 2A for RIE-1
cells, Figure S1B for RK3E cells) or suppressed anoikis (Figure 2B,
Figure S1C) in the absence of BDNF. This was in contrast to what
was observed for the constitutively active and ligand-independent
TPR-TRKB mutant, which did transform RIE-1 and RK3E cells
and suppressed anoikis in the absence of exogenous BDNF,
consistent with our previous report [25].
Next, we activated the wild-type and mutant receptors by stably co-
expressing human BDNF, both in RIE-1 (Figure 3A) and RK3E cells
(Figure S1D). Consistent with our previous observations [24–26], for
cells expressing wild-type TRKB+BDNF this resulted in EMT-like
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of E-cadherin (Figure 3C and Figure S1F) and anoikis suppression
(Figure 3D, Figure S1G). The same was seen for cells expressing
TRKB
L138F+BDNF and TRKB
P507L+BDNF. By contrast,
TRKB
T695I–a n dT R K B
D751N–expressing cells were impaired in their
response to BDNF (Figure 3B,C,D, Figure S1E,F,G). These results
show that, unexpectedly,TRKB
T695Iand TRKB
D751N are impaired in
their ability to transform rat epithelial cells in vitro.F u r t h e r m o r e ,
TRKB
L138F and TRKB
P507L are indistinguishable from wild-type
TRKB in this setting.
Responsiveness of human cancer-derived TRKB mutants
to BDNF
We have previously shown that TRKB-mediated oncogenic
transformation of RIE-1 cells critically depends on TRKB kinase
activity [25,26]. In search of a biochemical explanation for the
unanticipated results described above, we determined whether the
cancer-derived TRKB mutants differ from wild-type TRKB in
their responsiveness to BDNF. To measure TRKB activation, we
used RIE-1 cells expressing wild-type or mutant TRKB but no
ligand, and stimulated the cells with a physiologically relevant
range of recombinant BDNF. In line with our previous studies
[25,26], this induced autophosphorylation of wild-type TRKB
(Figure 4A and 4B), and led to the activation of two major
downstream signaling pathways [22]: the PI3K pathway (resulting
in phosphorylation of AKT/PKB; Figure 4C) and the MAPK
pathway (resulting in phosphorylation of MAPK/ERK;
Figure 4D). Exposure to 1 ng/ml BDNF was sufficient to elicit
wild-type TRKB autophosphorylation and activate the MAPK
pathway, whereas higher concentrations of BDNF were required
to activate AKT (Figure 4B,C,D and data not shown). TRKB
L138F
and TRKB
P507L responded to BDNF similarly to wild-type
TRKB. Consistent with their inability to suppress anoikis,
TRKB
T695I was only partially activated by BDNF, while
TRKB
D751N was completely unresponsive to BDNF, identical to
kinase-inactive TRKB
K588M (Figure 4). These results show that
TRKB
T695I and TRKB
D751N display reduced responsiveness to
BDNF stimulation in rat epithelial cells, whereas TRKB
L138F and
TRKB
P507L behave indistinguishably from wild-type TRKB.
Oncogenic potential of human cancer-derived TRKB
mutants expressed in rat epithelial cells
Next, we tested the oncogenic potential of the TRKB mutants in
vivo, in mouse xenograft experiments. We subcutaneously
inoculated Balb/c nude mice with wild-type or mutant TRKB-
expressing cells. In the absence of BDNF, only wild-type TRKB-,
TRKB
L138F- and TRKB
P507L-expressing RIE-1 cells (Figure 5A,B,
Figure S2A,B) and RK3E cells (Figure S2E,F) formed large tumors
with short latencies, but none of the TRKB
T695I- or TRKB
D751N-
expressing cells did. Similar to this, also in the presence of co-
expressed BDNF, TRKB
L138F and TRKB
P507L caused tumors
Figure 2. Transforming potential of human cancer-derived
TRKB point mutants in vitro. (A) Morphology of RIE-1 cells expressing
mutant or wild-type TRKB, photographed at 50x magnification. (B) Anoikis
assay, in which cells described in (A) were seeded onto ULC plates and
scanned at 1x magnification 9 days later (7 days for TPR-TRKB).
doi:10.1371/journal.pone.0016871.g002
Figure 1. Identification of human cancer-derived TRKB point mutants and generation of cell systems. (A) Sequencing analysis of gDNA
from NCI-H2009 cells harboring the TRKB
L138F mutation (left panel) and from MDA-MB-435 cells harboring the TRKB
P507L mutation (right panel).
Asterisks (*) indicate the respective mutated bases. Black letters denote wild-type residues, red letters denote mutant residues. (B) Schematic
overview over all cancer-derived TRKB point mutations analyzed in this study. LRM: Leucine-Rich Motif, Ig: Immunoglobulin-like domain, TM:
transmembrane domain. Numbers indicate positions of amino acid residues. (C) Expression levels of mutant or wild-type TRKB in RIE-1 cells, analyzed
on immunoblot (IB). Tubulin serves as loading control. Numbers represent quantification of TRKB signal, normalized to alpha-tubulin, and relative to
Vector control. (D) Cell surface biotinylation assay showing that at least a significant fraction of all TRKB mutants localizes to the cell membrane. Total
cell surface proteins were biotinylated with Sulfo-NHS-LC-Biotin, lysed and TRKB was immunoprecipitated (IP) with TRK antibody (C-14, C-13 for
control). After gel electrophoresis, biotinylated TRKB was visualized with streptavidin-HRP and total TRKB with TRK antibody (C-14). All wild-type and
mutant TRKB proteins became biotinylated (upper left panel). On the right hand side the specificity of the assay is demonstrated: biotin signal was
only detected for full-length TRKB (upper right panel, second lane), but not for cytosolic, truncated TPR-TRKB [25] (third lane, expected at ,50 kD),
and not in the control IP (lane 4) or in the absence of Sulfo-NHS-LC-Biotin (lane 5). IP of total full-length and truncated TRKB is shown in bottom
panels. Arrowheads indicate full-length TRKB, arrow indicates truncated TPR-TRKB (just below Ig heavy chains).
doi:10.1371/journal.pone.0016871.g001
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(Figure 5C,D, Figure S2C,D and Figure S2G,H). In this setting,
RIE-1 TRKB
T695I+BDNF–expressing cells also formed tumors,
but with a statistically significant delay, compared to RIE-1
TRKB
wt+BDNF–expressing cells (Figure 5C, S2C). Of note, when
1*10
5 cells were inoculated, also RIE-1 TRKB
D751N+BDNF-
expressing cells formed tumors, but with a significant longer
latency than those induced by RIE-1 TRKB
wt+BDNF–expressing
cells (data not shown). In RK3E cells, expression of TRKB
D751N
did not lead to tumor formation, even with high cell numbers and
in the presence of BDNF, whereas RK3E TRKB
T695I+BDNF-
expressing cells formed tumors with a significant longer latency
compared to RK3E TRKB
wt+BDNF-expressing cells (Figure
S2G). Notwithstanding some differences between the two cell
lines, overall, these findings indicate that TRKB
T695I and
TRKB
D751N are impaired in transforming rat epithelial cells also
in vivo. Furthermore, neither TRKB
L138F nor TRKB
P507L displays
increased oncogenic activity compared to wild-type TRKB.
BDNF responsiveness of human colon cancer-derived
TRKB
T695I and TRKB
D751N expressed in colon cancer cells
One possible explanation for the impaired activity of
TRKB
T695I and TRKB
D751N in the assays described above is
that we performed them in an aphysiological cellular context.
Indeed, the wiring of the intracellular signaling networks and the
expression pattern of TRKB regulatory factors may not be
Figure 3. Transforming potential of BDNF-activated TRKB point mutants in vitro. (A) RIE-1 cells expressing mutant or wild-type TRKB were
transduced with BDNF and analyzed on immunoblot (IB). Arrowhead indicates position of BDNF. Tubulin serves as loading control. (B) Morphologic
transformation of RIE-1 cells co-expressing mutant or wild-type TRKB and BDNF, photographed at 50x magnification. (C) The epithelial marker E-
cadherin is downregulated in TRKB-induced, morphologically transformed, cells, as assessed by immunoblot (IB) analysis. b-actin serves as loading
control. (D) Anoikis suppression by mutant or wild-type TRKB+BDNF in cells described in (A). Cells were scanned at 1x magnification 9 days after
seeding onto ULC plates.
doi:10.1371/journal.pone.0016871.g003
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the TRKB mutants in their original context, that is, in the tumor
cells in which they were originally identified. However, there are
no cell lines available that express TRKB
T695I or TRKB
D751N
endogenously. Moreover, to our knowledge there is no primary
human colon epithelial cell line available. Aiming to use a
physiologically relevant cell system, we transduced COLO 205
and Caco-2 human colon carcinoma cells with TRKB
T695I or
TRKB
D751N and obtained polyclonal populations stably express-
ing either receptor. We stimulated these cells with recombinant
BDNF and subsequently measured TRKB autophosphorylation
and activation of downstream effectors. Similar to what was
observed in RIE-1 cells, in both COLO 205 and Caco-2 cells,
TRKB
T695I and TRKB
D751N were less abundantly phosphorylat-
ed than wild-type TRKB upon stimulation with BDNF (Figure 6).
ERK was phosphorylated upon TRKB stimulation only in Caco-2
cells, but not in COLO 205 cells (Figure 6C,D). This is probably
because COLO 205 cells harbor a BRAF
V600E mutation (www.
sanger.ac.uk/genetics/CGP/cosmic), which is constitutively active
and stimulates MAPK signaling [16]. Upon stimulation of Caco-2
cells with BDNF, neither TRKB
T695I nor TRKB
D751N induced
ERK phosphorylation (Figure 6D). Together, these results show
that the TRKB
T695I and TRKB
D751N mutants are less active not
only in rat epithelial cells but also in two human colon carcinoma
cell lines.
Knockdown of endogenous TRKB
L138F and TRKB
P507L in
human tumor cell lines
The fact that TRKB
L138F and TRKB
P507L are endogenously
expressed in tumor cell lines gave us the possibility to investigate
whether they are required for their oncogenic phenotype. We
depleted TRKB
L138F and TRKB
P507L from NCI-H2009 and
MDA-MB-435 cells, respectively, by RNA interference with two
independent, non-overlapping short hairpin (sh) RNA constructs.
We achieved ,75% downregulation of TRKB in NCI-H2009
cells (Figure 7A). However, this affected neither cell morphology
(Figure 7B top panel) nor anoikis resistance (Figure 7B bottom
panel). Likewise, ,80% downregulation of TRKB in MDA-MB-
435 cells (Figure 7C) had no effect on cell morphology (Figure 7D
upper panel) and anoikis resistance (Figure 7D bottom panel).
Consistent with these observations, E-cadherin levels were not
changed upon TRKB knockdown in either cell line (Figure 7E).
Furthermore, no effect on cell proliferation was observed (data not
shown). Notwithstanding that TRKB was not fully depleted in
either cell line, these results suggest that (mutant) TRKB in NCI-
H2009 and MDA-MB-435 cells is not a major driver of their
transformed phenotype.
Figure 4. Responsiveness of human cancer-derived TRKB
mutants to BDNF. (A) RIE-1 cells expressing wild-type or mutant
TRKB were stimulated with 10 ng/ml recombinant BDNF and analyzed
for phospho-tyrosine (pY) and total TRK content by immunoprecipita-
tion (IP) and subsequent immunoblot (IB) analysis. (B) RIE-1 cells
expressing wild-type or mutant TRKB were stimulated with 1 ng/ml
recombinant BDNF and analyzed for phospho (p) and total TRK. (C) RIE-
1 cells expressing wild-type or mutant TRKB were stimulated with
10 ng/ml recombinant BDNF and analyzed for phospho- (p) AKT and
total AKT. PI3K inhibitor LY294002 was applied to confirm the identity
of the pAKT signal indicated by the arrowhead. Asterisk (*) indicates a
non-specific band. The samples loaded in lanes two and three serve as
controls and were derived from a replicate experiment performed
under identical conditions. (D) RIE-1 cells expressing wild-type or
mutant TRKB were stimulated with 1 ng/ml recombinant BDNF and
analyzed for phospho- (p) ERK and total ERK. For all panels, the
numbers underneath indicate quantification of the phospho-specific
signals, normalized to the total signals and relative to those of wild-type
TRKB.
doi:10.1371/journal.pone.0016871.g004
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Three somatic, non-synonymous point mutations of TRKB have
been reported in the early large-scale sequencing studies in human
cancers: two in colorectal tumors, TRKB
T695I and TRKB
D751N
[17], and one in a lung adenocarcinoma cell line, TRKB
L138F [19].
We identified one additional TRKB point mutation, TRKB
P507L,i n
the MDA-MB-435 human melanoma cell line. Although some of
these mutants havebeen proposed as candidatecancer-drivinggenes
[17], unexpectedly, our analysis in rat epithelial cells and in human
tumor cell lines failed to provide support for a gain-of-function effect
for any of the fourTRKB point mutations.Infact, the twocolorectal
tumor-derived TRKB point mutations were associated with even
reduced kinase activity and oncogenic potential, compared to wild-
type TRKB. As a cautionary note, one has to bear in mind that we
did not test the colorectal tumor-derived TRKB mutants in their
original context, namely the tumors that endogenously express
TRKB
T695I or TRKB
D751N, while cell lines derived thereof are
unavailable. Nonetheless, exposure to BDNF of both rat epithelial
and human colon cancer cells expressing these mutants resulted in
reduced receptor activation of TRKB
T695I and almost no activation
of TRKB
D751N. This strongly suggests that these mutants have
impaired enzymatic activity in the context of BDNF stimulation. It
even raises the possibility that TRKB
T695I and TRKB
D751N may act
in a dominant negative fashion, and that wild type TRKB may also
have tumor suppressing activity (or a dual function) in colon cancer,
but further studies will be required to address these important issues.
We cannot exclude the possibility that the responsiveness of
TRKB
T695I and TRKB
D751N to other TRKB ligands may be
different from that to BDNF. We can also not formally exclude the
possibility that TRKB
T695I and TRKB
D751N might have been
selected for in the original tumors, contributing to tumor formation
with functions that are different from those we tested in vitro. These
issuesnot withstanding,wefeelitisfairto saythat thesemutationsdo
not meet conventional criteria for mutational activation of receptor
kinases.
Theoretically, all mutations residing in the cytoplasmic part of
the receptor could influence the binding of adaptor proteins or
substrates of TRKB, independent of the effect on kinase activity.
The presence and function of these binding partners would
depend on cellular context and may be different in different cell
lines. Although the prototypic mechanism for oncogenic function
of tyrosine kinases is constitutive or enhanced kinase activity with
altered downstream signaling [37], receptor tyrosine kinases can
have also kinase-independent functions that contribute to cancer.
Figure 5. Oncogenic potential of human cancer-derived TRKB mutants expressed in RIE-1 cells. (A) 1*10
6 RIE-1 cells expressing TRKB
(wild-type or mutant) were subcutaneously injected into both flanks of nude mice. n=5 for wt and P507L, n=4 for T695I and D751N. (B) 1*10
6 RIE-1
cells expressing TRKB (wild-type or mutant) were subcutaneously injected into both flanks of nude mice. n=4 for both cell lines. (C) 1*10
4 RIE-1 cells
co-expressing BDNF and TRKB (wild-type or mutant) were subcutaneously injected into nude mice. n=6 for wt and P507L, n=3 for T695I and D751N.
(D) 1*10
5 RIE-1 cells co-expressing BDNF and TRKB (wild-type or mutant) were subcutaneously injected into nude mice. n=4 for both cell lines. In all
experiments, mice were sacrificed when tumor burden reached 2 cm
2 and Kaplan-Meier survival curve is shown. Statistical significance was
determined with a Log-Rank test.
doi:10.1371/journal.pone.0016871.g005
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its kinase activity, interacts with and thereby stabilizes sodium/
glucose cotransporter 1 (SLGT1) [38]. Downregulation, but not
enzymatic inhibition, of EGFR leads to reduced SLGT1 levels,
reduced glucose uptake and autophagy of tumor cells [38].
Whether a similar function is also associated with TRKB is not
known. A recent study suggests that the kinase-deficient TRKB-
T1 splice variant, upon artificial overexpression, may stimulate
metastasis of pancreatic adenocarcinoma cells [39]. More research
is required to elucidate kinase-independent functions of TRKB
and their contribution to malignant disease, in particular to
address any role of the endogenous protein in cancer cells.
We have identified and characterized also a novel TRKB point
mutation, TRKB
P507L, which we isolated from the MDA-MB-435
tumor cell line. However, as a normal reference tissue sample
derived from the same patient is unavailable, it is unclear whether
this mutation corresponds to a somatic mutation in the tumor, to a
single nucleotide polymorphism (SNP) from this patient, or was
acquired during in-vitro passaging. However, this sequence
variation has not been reported in public SNP databases.
The ‘Cancer Gene Census’ database (http://www.sanger.ac.uk/
genetics/CGP/Census/) is a catalogue of genes whose mutations
have been causally implicated in cancer [2]. To date (December
2010), it comprises some ,436 different genes, amongst which are
the TRK receptor family members TRKA (NTRK1) and TRKC
(NTRK3), but not TRKB. TRKA and TRKC fusion oncoproteins
with constitutive kinase activity have been identified in papillary
thyroid (TRKA) [40] and in secretory breast [41] and congenital
fibrosarcoma tumors (TRKC) [42]. To date, no such structural
mutations for TRKB have been reported in human cancers.
Nonetheless, as TRKB is overexpressed in several human
malignancies, including neuroblastoma, pancreatic and prostate
adenocarcinoma, it has been suggested as a potential target for
anticancer therapy [43,44]. As our analysis presented here fails to
show a gain of function effect for four cancer-derived TRKB point
mutations, further research will be required before TRKB can be
added to the listofbonafidecancer genes. If the TRKB point mutants
analyzed in this study indeed fail to display gain-of-function
transforming properties, this would suggest that they represent
passenger mutations and did not drive tumor formation. This may
alsobeindicatedbytherareoccurrenceofthesemutations,which,to
our knowledge, have not been reported again after their original
identification. More recently, four more TRKB point mutations
have been identified in human Large Cell NeuroEndocrine
Carcinomas (LCNEC) of the lung [45] and another six in lung
adenocarcinomas [46]. Although all four LCNEC-derived muta-
tions and four out of the six adenocarcinoma-derived mutations
locate to the kinase domain of TRKB, the effect of these novel
mutations on gene function remains to be determined.
Figure 6. BDNF responsiveness of human colon cancer-derived TRKB
T695I and TRKB
D751N expressed in colon cancer cells. (A) COLO
205 cells and (B) Caco-2 cells expressing wild-type or mutant TRKB were stimulated with 10 ng/ml recombinant BDNF and analyzed for phospho-
tyrosine (pY) content by immunoprecipitation (IP) and subsequent immunoblot (IB) analysis. (C) Cell lysates of COLO 205 cells from (A) and, (D)
lysates of Caco-2 cells from (B) were analyzed for phospho (p) and total TRK and (p)ERK. The MEK inhibitor U0126 was applied to confirm the identity
of the pERK signals. b-actin serves as loading control.
doi:10.1371/journal.pone.0016871.g006
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the ongoing efforts for systematic, large-scale cancer genome
sequencing, there is a need for functional studies assessing the biological
consequences, particularly the oncogenic potential, of newly discovered
cancer-associated mutations. Similar conclusions have been reached by
others, for example, on the receptor kinase FLT3 [47]. Our results
suggest that the acquisition of point mutations may not correspond to a
primary mechanism of TRKB activation in human cancer.
Materials and Methods
Sequencing and vector constructs
Genomic DNA for partial sequencing of the TRKB gene was
isolated by first lysing cells overnight at 55uC in 0.1 M TRIS
pH 8.5+0.2 M NaCl +5 mM EDTA +0.2% SDS + 100 mg/ml
ProtK, subsequently purifying gDNA with phenol/chloroform/
isoamylalcohol and precipitation in isopropanol. Finally, gDNA
was washed with 70% ethanol and dissolved in TE. PCR primers
used were for LRM domain: exon 7 forward: GTGAAAGAGA-
GAGAGATCTGG-39, exon 7 reverse: TGGTATAAAAATA-
GATCTGC-39, for kinase domain: exon 16 forward:
59TGGGGAGTGAGTGCTAACTGG-39, exon 16 reverse: 59-
CGCCAGTCATCCCTATCAGG-39, exon 17 forward: 59-GC-
CATTTGGGGTGGACTG-39, exon 17 reverse: 59-GGAT-
GTGCCCCAAATGTCC-39, exon 18 forward: 59-CTCAGTAT-
CATAGGGCCCAC-39, exon 18 reverse: 59-GTCCCTTG-
TTCCCTCCCATG-39, exon 19 forward: 59-CCAGCAGCTA-
CAGGGTGGGGG-39, exon 19 reverse: 59-CCAGCCTCCA-
Figure 7. Knockdown of endogenous TRKB
L138F and TRKB
P507L in tumor cell lines. (A) qRT-PCR demonstrating knockdown of TRKB mRNA
levels with two non-overlapping short hairpins (sh). Average values of three independent measurements are shown, error bars represent standard
deviations. (B) Knockdown of TRKB neither affects morphology of adherently growing NCI-H2009 cells, photographed at 50x magnification (top
panel), nor anoikis resistance of NCI-H2009 cells in suspension (bottom panel). ULC plates were scanned at 1x magnification 6 days after seeding.
(C) qRT-PCR demonstrating knockdown of TRKB mRNA levels with two non-overlapping short hairpins. Average values of three independent
measurements are shown, error bars represent standard deviations. (D) Knockdown of TRKB neither affects morphology of adherently growing MDA-
MB-435 cells, photographed at 50x magnification, nor anoikis resistance of MDA-MB-435 cells in suspension (bottom panel). ULC plates were scanned
at 1x magnification 6 days after seeding. (E) Knockdown of TRKB in NCI-H2009 and MDA-MB-435 cells does not affect E-cadherin protein levels, as
assessed by immunoblot (IB) analysis. Long and short exposures of the same blot are shown. b-actin serves as loading control.
doi:10.1371/journal.pone.0016871.g007
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GCAGCTCCC-39, exon 20 reverse: 59-CCTGACATGG-
TCTTCCAACCC-39. PCR fragments were purified on agarose
gels and 3-12 ng of DNA was subjected to sequencing analysis
using the same primers as mentioned above. Sequences were
analyzed with 4peaks software (http://mekentosj.com/4peaks/).
Cloning and expression of human TRKB (NM_006180.3),
TRKB
K588M, TPR-TRKB, and human BDNF (NM_170735) have
been described before [25]. All cancer-derived TRKB point mutants
were generated by site-directed mutagenesis (Stratagene) according to
the manufacturer’s instructions. Primers used were for L138F: 59-
CATTTCCGTCACTTTGACTTGTCTGAAC-39 for P507N: 59-
CCAATGGGAGTAACACTCTATCTTCTTCGGAAGGTGGC-
CC-39, for T695I: 59-GCACCGCGATTTGGCCATCAGGAA-
CTGCCTGGTCGGGG-39, for D751N: 59-GGAAATTCAC-
GACGGAAAGCAACGTCTGGAGCCTGGGG-39and the respec-
tive complementary primers (the bold letter is indicating base
substitution C to T for L138F, P705L and T695I, and G to A for
D751N). All TRKB mutants and BDNF were expressed from the
retroviral pBabe-puro (pBP)and pBabe-hygro (pBH) vectors.Lentiviral
short hairpin- (sh-) RNA constructs were generated by cutting
pRetroSuper-puro (pRS) [48] sh-EGFP (GCTGACCCTGAAGTT-
CATC), pRS sh-TRKB#1 (GTAACCTGGTTTCCAAACA) and
pRS sh-TRKB#2 (GTAATGCTGTTTCTGCTTA) with NsiI/
klenow and XhoI and ligating the respective inserts into an EcoRI/
klenow and XhoI–digested HIV-CSCG-EGFP vector, removing
EGFP from HIV-CSCG and inserting H1-promotor/shRNA/
puromycin-resistance. The sequences in brackets correspond to the
targeting sequences of the respective shRNAs.
Cell culture, retroviral transduction and anoikis assays
RIE-1 cells (a kind gift from R.D. Beauchamp and K.D. Brown
[49]), RK3E cells (ATCC), COLO 205 cells (ATCC), Caco-2 cells
(ATCC) and MDA-MB-435 cells (ATCC) were cultured in DMEM
medium (Gibco) supplemented with 9% fetal calf serum (Greiner
bio-one) and penicillin+streptomycin (Gibco). NCI-H2009 cells (a
kind gift from F. Kaye [50]) were cultured in RPMI 1640 medium
with the same supplements as described above. COLO 205 and
Caco-2 cells were transduced with pLZRS-Ecotropic Receptor-
IRES-Neo by amphotropic retrovirus produced in BING cells.
Retroviral transduction and generation of stable cell pools was done
as previously described [25], http://www.stanford.edu/group/
nolan/retroviral_systems/phx.html). NCI-H2009 and MDA-MB-
435 cells were transduced with lentivirus produced in HEK293
cells.
To induce anoikis we seeded 4*10
5 freshly trypsinized cells into
non-adhesive Ultra Low Cluster (ULC) six-well cell culture dishes
(Costar). ULC plates were scanned on an Epson Perfection 4990
Photo scanner and photographs were taken with a Sony DSC-75
digital camera.
Immunoblotting, immunoprecipitation and antibodies
Cells were lysed in RIPA buffer and analyzed on immunoblots
as described before [26]. Antibodies used were: TRK (C-14, Santa
Cruz), TRKB (80E3, Cell Signaling), TRKB [TK-] (C-13, Santa
Cruz), BDNF (N20, Santa Cruz), E-cadherin (BD Bioscience),
phospho-tyrosine (4G10, Upstate), phospho-TRK (phospho-TrkA
pTyr
490, Sigma), phospho-AKT (pSer
473, Cell Signaling), AKT1/
2 (H-136, Santa Cruz), phospho-ERK (phospho p44/42 MAPK
pThr
202/pTyr
204, Cell Signaling), ERK (p44/42 MAPK, Cell
Signaling), b-actin (AC74, Sigma) and a-tubulin (DM 1A, Sigma).
Antibodies were diluted 1:1000-1:5000 in blocking solution, either
4% Protifar plus (Nutricia) or 4% bovine serum albumin + 1/50
Western Blocking Reagent (Roche). Where indicated, signal
intensities were quantified with ImageJ 1.44j software (http://
imagej.nih.gov/ij).
For immunoprecipitation, equal amounts of lysates were
incubated with 0.5 mg TRK (or TRKB [TK-] as a control)
antibody for 2 h at 4uC. Proteins were immobilized with Protein A
sepharose beads, washed four times with lysis buffer and
immunoblotted for analysis.
For cell surface protein biotinylation assay, cells were washed
three times for 10 minutes with ice-cold PBS (pH 8.0) and
subsequently incubated for 25 minutes at 4uC with 2 mg/ml
freshly prepared Sulfo-NHS-LC-Biotin (Pierce) in PBS pH 8.0.
We then quenched excess biotin reagent with PBS + 100 mM
glycine by rinsing twice and incubating the cells for 20 minutes at
4uC. Subsequently, cells were lysed, processed for immunoprecip-
itation and analyzed by immunoblotting as described above.
Biotinylated proteins were detected with StreptABComplex/HRP
(Dako Cytomation).
Stimulation with BDNF
Serum-starved cells were stimulated for 5 minutes with serum-
free DMEM supplemented with recombinant human BDNF
(Peprotech). To inhibit PI3K and MEK activity, cells were pre-
treated with 20 mM LY294002 (Calbiochem) and 10 mM U0126
(Cell Signaling) for 30 minutes and subsequently stimulated with
recombinant human BDNF in the presence of LY294002 and
U0126.
In vivo assays
Age-matched groups of female Balb/c nude mice were
subcutaneously injected with 1*10
4, 1*10
5 or 1*10
6 cells into both
flanks. Whereas experiments were generally carried out with pBP-
TRKB (and co-expressed pBH-BDNF where indicated), pBH-
TRKB
L138F, pBH-TRKB
wt and pBP-BDNF were used for in-vivo
assays, shown in independent figure panels. Mice were inspected
twice a week and euthanized by CO2 when the total tumor burden
reached 2 cm
3 or when tumors started to ulcerate. Tumor size was
measured with a caliper and tumor volume calculated by the
formula (a*b
2)/2, with a being the longest diameter and b the
perpendicular diameter of the tumor. Kaplan-Meier survival
curves were plotted with SPSS 15.0 and statistical significance was
determined with Log-Rank tests.
This study and all the procedures applied were approved by the
Institutional Animal Experiment Ethics Committee (‘‘Dierenex-
perimentencommissie’’ NKI: DEC-nr. 04089), and all efforts were
made to minimize suffering of the animals.
Quantitative reverse transcriptase PCR (qRT-PCR)
Total RNA was isolated using Trizol (Invitrogen) and treated
with DNase for 1 h at 37uC (Promega). cDNA was prepared using
the reverse transcriptase kit from Invitrogen. Primers were
designed with Primer Express software: TRKB-forward: 59-
AACAGAAGTAATGAAATCCCTTCCA-39, TRKB-reverse:
59-CAGCATAGACCGAGAGATGTTCC-39, RPL13 forward:
59-GAGACAGTTCTGCTGAAGAACTGAA-39, RPL13 re-
verse: 59-TCCGGACGGGCATGAC-39. Detection was done
with SYBR green master mix (Applied Biosystems) on an ABI
Prism 7000 thermal cycler (Applied Biosystems). RNA levels were
normalized against human RPL13.
Supporting Information
Figure S1 Transforming potential of human cancer-
derived TRKB point mutants in RK3E cells in vitro. (A)
RK3E cells expressing wild-type or mutant TRKB analyzed on
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PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16871immunoblot (IB). Tubulin serves as loading control. (B) Morphol-
ogy of RK3E cells expressing wild-type or mutant TRKB,
photographed at 50x magnification. (C) Anoikis assay. Cells
described in (A) were seeded on ULC plates and scanned at 1x
magnification 5 days later. (D) Cells described in (A) were
transduced with BDNF and analyzed on immunoblot (IB).
Arrowhead indicates position of BDNF, which was expressed to
lower levels in the sample loaded in the first lane. Tubulin serves as
loading control. (E) Morphologic transformation of RK3E cells co-
expressing mutant or wild-type TRKB and BDNF described in
(D), photographed at 50x magnification. (F) The epithelial protein
E-cadherin is downregulated in TRKB-induced, morphologically
transformed, cells, as assessed by immunoblot (IB) analysis. b-actin
serves as loading control. (G) Anoikis suppression by wild-type or
mutant TRKB+BDNF in RK3E cells described in (D). ULC plates
were scanned at 1x magnification 5 days after seeding.
(TIF)
Figure S2 Oncogenic potential of human cancer-derived
TRKB mutants in RIE-1 and RK3E cells in vivo. (A)
Tumor growth curve for mice shown in Figure 5A. T695I- and
D751N-expressing cells did not form tumors for at least 100 days.
Data points in Figures S2A-D represent mean values of total
tumor burden per mouse, error bars depict standard deviation. (B)
Tumor growth curve for mice shown in Figure 5B. (C) Tumor
growth curve for mice shown in Figure 5C. BDNF+D751N-
expressing cells did not form tumors for at least 100 days. (D)
Tumor growth curve for mice shown in Figure 5D. (E) 1*10
6
RK3E cells expressing TRKB (wild-type or mutant) were
subcutaneously injected into both flanks of nude mice. n=3 for
wt and P507L, n=4 for T695I and D751N (F) 1*10
6 RK3E cells
expressing TRKB (wild-type or mutant) were subcutaneously
injected into both flanks of nude mice. n=4 for both cell lines. (G)
1*10
5 RK3E cells co-expressing BDNF and TRKB (wild-type or
mutant) were subcutaneously injected into both flanks of nude
mice. n=3 for each cell line. Statistical significance was
determined with a Log-Rank test. (H) 1*10
5 RK3E cells co-
expressing BDNF and TRKB (wild-type or mutant) were
subcutaneously injected into both flanks of nude mice. n=4 for
both cell lines. In all experiments, mice were sacrificed when
tumor burden reached 2 cm
2. Kaplan-Meier survival curve is
shown. Different litters of mice were used for the different
experiments, possibly contributing to experimental variation
between experiments.
(TIF)
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